Adicet Bio, Inc.
ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity inā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.41
Price-0.12%
-$0.01
1Y
Price
Market Cap
$700.375m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR+14.2%
5y CAGREarnings
-$115.014m
+1.8%
1y CAGR-28.2%
3y CAGR-24.3%
5y CAGREPS
-$1.26
+5.3%
1y CAGR-9.9%
3y CAGR-3.7%
5y CAGRBook Value
$109.142m
$140.479m
Assets$31.337m
Liabilities$15.536m
DebtDebt to Assets
11.1%
-0.1x
Debt to EBITDAFree Cash Flow
-$100.362m
-7.3%
1y CAGR-20.7%
3y CAGR-14.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company